Immune checkpoint inhibitor-related myocarditis: a comprehensive analysis of clinical manifestations and prognostic factors.

ABSTRACT:

Background

Immune checkpoint inhibitors-related myocarditis (ICI-myocarditis) is a rare but potentially lethal complication of cancer immunotherapy. Extensive information concerning risk factors and outcomes is still insufficient.

Methods

This multicenter retrospective study enrolled 161 patients diagnosed with biopsy-proven or clinically diagnosed ICI-myocarditis. We performed thorough studies of clinical characteristics and management approaches. Time-to-event analyses, encompassing landmark analysis, and competing risk models, were employed to identify early mortality predictors and evaluate long-term prognosis in survivors.

Results

ICI-myocarditis typically generally manifested early (median 4 weeks following ICI initiation), with mortality primarily occurring wit

SUBMITTER: Fan Y 

PROVIDER: S-EPMC12808996 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature